PlainRecalls
FDA Drug Moderate Class II Terminated

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 62037-577-01) and b) 1000 (NDC 62037-577-10), Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa, Distributed by: Actavis Pharma, Inc., Parsippany, NJ

Reported: July 1, 2020 Initiated: June 2, 2020 #D-1332-2020

Product Description

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 62037-577-01) and b) 1000 (NDC 62037-577-10), Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa, Distributed by: Actavis Pharma, Inc., Parsippany, NJ

Reason for Recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
a) 15,329 bottles and b) 137 bottles
Distribution
Product was distributed throughout the United States, including Puerto Rico.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 62037-577-01) and b) 1000 (NDC 62037-577-10), Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa, Distributed by: Actavis Pharma, Inc., Parsippany, NJ. Recalled by Teva Pharmaceuticals USA. Units affected: a) 15,329 bottles and b) 137 bottles.
Why was this product recalled?
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Which agency issued this recall?
This recall was issued by the FDA Drug on July 1, 2020. Severity: Moderate. Recall number: D-1332-2020.